4.95
-0.12(-2.37%)
Currency In USD
Address
155 Bovet Road
San Mateo, CA 94402
United States of America
Phone
650-561-8600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
July 17, 2023
| Name | Title | Pay | Year Born |
| Mr. David A. Happel | Chief Executive Officer, President & Director | 836,183 | 1962 |
| Dr. George W. Kemble Ph.D. | Executive Chairman of the Board | 484,003 | 1962 |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer | 649,334 | 1963 |
| Mr. Robert D'Urso | Senior Vice President of New Products | 0 | N/A |
| Mr. Urs Greber Ph.D. | Co-Founder | 0 | N/A |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder | 0 | N/A |
| Mr. Thierry Chauche | Chief Financial Officer & Principal Accounting Officer | 0 | 1976 |
| Ms. Elizabeth Rozek Esq., J.D. | General Counsel & Chief Compliance Officer | 0 | 1972 |
| Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research & Development | 0 | N/A |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.